Description
Vyepti (eptinezumab-jjmr) is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a neuropeptide involved in the pathophysiology of migraine. By binding to CGRP and preventing its interaction with its receptor, Vyepti reduces migraine frequency and severity. It is indicated for the preventive treatment of migraine in adults. Vyepti is administered as a quarterly intravenous infusion and provides sustained reduction in migraine days, offering a treatment option for patients seeking infrequent dosing and rapid onset of effect.
| Fact Table |
| Formula | C6464H9978N1718O2022S44 |
| License | US FDA (2020) |
| Bioavailability | ~100% (IV) |
| Legal status | Rx-only |
| Chemical Name | Eptinezumab |
| Elimination half-life | 27 days |
| Dosage (Strength) | 100 mg/mL or 300 mg/100 mL (IV infusion every 3 months) |
| Pregnancy | Consult a doctor (limited human data) |
| Brands | Vyepti |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 123844991 |
| MedlinePlus | a620036 |
| ChEBI | 183098 |
| ATC code | N02CD06 |
| DrugBank | DB15110 |
| KEGG | D11917 |
| Routes of administration | Intravenous infusion |
Directions
Vyepti is administered by intravenous infusion over approximately 30 minutes once every 3 months (12 weeks). The recommended dose is 100 mg, though 300 mg may be used based on clinical response and physician judgment. No dose adjustment is necessary for patients with renal or hepatic impairment. The solution must be diluted in 100 mL of 0.9% Sodium Chloride Injection prior to administration. Patients should be monitored during and after infusion for signs of hypersensitivity.
Ingredients
Each single-dose vial of Vyepti contains:
- Eptinezumab-jjmr (100 mg/mL)
- L-histidine hydrochloride monohydrate
The product is preservative-free and must be diluted prior to use.
Contraindications
Vyepti is contraindicated in patients with:
- Known serious hypersensitivity to eptinezumab-jjmr or any component of the formulation
Cautions
Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. These may occur during or shortly after infusion. Discontinue treatment immediately if serious reactions occur. Safety and efficacy have not been established in pediatric patients or for the treatment of acute migraine attacks. The use of Vyepti during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus, as CGRP plays a role in uteroplacental blood flow.
Side Effects
Common side effects of Vyepti include:
- Hypersensitivity reactions
Serious but less common adverse effects include:
- Infusion-related reactions
Patients should be observed during and after the infusion for any adverse effects, particularly during the initial administration.
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14405
Prescription Required